Pre-emptive diagnosis and treatment of fungal infections-evaluation of a single-centre policy

Clinical Microbiology and Infection

Volumn 18, Issue 2, 2012, Pages 189-194

  Schneider, T ^a   Halter, J ^a   Heim, D ^a   Passweg, J ^a   Stern, M ^a   Tichelli, A ^a   Weisser, M ^a   Gerull, S ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antifungal; Invasive fungal disease; Pre emptive treatment

Indexed keywords

FLUCONAZOLE; GALACTOMANNAN;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; AUTOPSY; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; FEMALE; GALACTOMANNAN TEST; HOSPITAL POLICY; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SYSTEMIC MYCOSIS;

EID: 84856233213     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03589.x     Document Type: Article

References (17)

1. Cornely OA, Bohme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the infectious diseases working party of the German Society for Haematology and Oncology. Haematologica 2009; 94: 113-122.
2. Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402-409.
3. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668-672.
4. Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977; 86: 539-543.
5. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
6. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
7. Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-5118.
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC/msg) consensus group. Clin Infect Dis 2008; 46: 1813-1821.
9. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
10. Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042-1051.
11. Girmenia C, Micozzi A, Gentile G et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667-674.
12. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003; 4: 974-990.
13. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
14. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250.
15. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (suppl 1): S49-58.
16. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-1601.
17. Hahn-Ast C, Glasmacher A, Muckter S et al. Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006. J Antimicrob Chemother 2010; 65: 761-768.